Top of this page
Skip navigation, go straight to the content
Nov 30, 2018
UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Oct 30, 2018
UCB tracking well towards full year financial outlook
Oct 23, 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Oct 23, 2018
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 19, 2018
• Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA® (certolizumab pegol) in this patient population when added to common background medications
Oct 18, 2018
On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored
Oct 18, 2018
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase
Aug 13, 2018
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
Jul 11, 2018
The AIM Movement provides support, information and a place to share stories about motherhood in women with chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and Crohn’s disease (CD).
May 29, 2018
• The U.S. Food and Drug Administration’s (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology
• CIMZIA Phase 3 psoriasis studies demonstrated significant and clinically meaningful improvements in biologic-naïve patients and those previously treated with biologics, with clinical benefit maintained through 48 weeks and the flexibility of two dose regimens that allow for tailored treatment1